Cell Signaling Technology, Inc. Announces License in Personalized Cancer Diagnostics
3/15/2011 10:31:20 AM
DANVERS, Mass.--(BUSINESS WIRE)--Cell Signaling Technology, Inc. (CST) of Danvers, MA, announced today that it has granted Ventana Medical Systems, Inc., a worldwide non-exclusive license to CST patent rights and proprietary antibody reagents relating to the detection of epidermal growth factor receptor (EGFR) mutations for the field of tissue-based in vitro diagnostic testing. Mutant forms of EGFR are important determinants in the clinical management of lung cancer.